MindMaze Therapeutics Enrolls First Patients in SwissNeuroRehab Study, Advancing At-Home Reimbursement Strategy in Europe

AI SummaryClose X

MindMaze Therapeutics Holding SA has enrolled the first patients in the SwissNeuroRehab study and launched the REACT-AVC study in France, both aimed at advancing its at-home neurorehabilitation reimbursement strategy in Europe. The SwissNeuroRehab consortium is an CHF 11.2 million Innosuisse-backed initiative involving multiple Swiss centers to validate technology-supported neurorehabilitation pathways. The REACT-AVC study at Hospices Civils de Lyon focuses on early outpatient and home-based stroke rehabilitation, mirroring the company's successful US reimbursement model. These studies are designed to generate clinical and health-economic data required by European payers, extending MindMaze's integrated care continuum from inpatient to home-based therapy.

Disclaimer*

UK 100

Latest directors dealings